Skip to main content

Table 2 Characteristics of patients in the control group

From: Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre

Patient

Age (years old)

Type of cancer

Staging of AKI

Hemoglobin level (g/dl)

Platelets count (G/l)

LDH ratio (x normal)

Serum Creatinine level at diagnosis (mg/l)

Hematological response

Renal response

Outcome / Time to death or time of last follow-up for still alive patients (months)

1

56

Pancreatic, NA

3

12.3

79

1.9

44

Yes

Partial

Deceased / 72 m

2

33

Ovarian, M+

2

6.2

58

1.4

18

Yes

Partial

Deceased / 10 m

3

80

Pancreatic, M+

2

7.3

81

1.7

10

Yes

Complete

Deceased / 14 m

4

65

Pancreatic, M+

3

9.7

70

1.2

35

Yes

Partial

Deceased / 18 m

5

74

Pancreatic, M+

3, RRT

9.7

34

2.9

35

No

No

Alive / 3 m

6

66

Pulmonary, NA

3, RRT

4

146

3.9

94

Yes

No

Deceased / 1 m

7

59

Pancreatic, M+

3

6.9

85

1.5

41

Yes

Partial

Alive / 3 m

8

55

Pancreatic, M-

3

8.7

100

3.0

41

Yes

No

Deceased / 2 m

9

78

Pancreatic, M-

3

7.2

450

1.0

29

Yes

Complete

Alive / 24 m

10

56

Breast, M+

2

7.5

61

1.0

17

Yes

Complete

Alive / 2 m

11

58

Hepatic, NA

3, RRT

10.4

42

6.5

32.4

Yes

No

Deceased / 8 m

12

60

Pancreatic, M+

3

8.7

202

2.5

23

Yes

No

Deceased / 7 m

13

52

Hepatic, M+

3

9.1

96

5.8

50

Yes

Partial

Deceased / 10 m

14

73

Pancreatic, NA

3

9.9

430

3.1

29

Yes

Partial

Deceased / 14 m

  1. TMA Thrombotic microangiopathy, AKI Acute kidney injury (AKI was assessed according to KDIGO classification 2012), LDH Lactate dehydrogenase, RRT Renal replacement therapy, M- No metastatic, M+ Metastatic, NA Data not available